Cutaneous side effects of vemurafenib: a case report and discussion

In 2011, the FDA approved the drug vemurafenib, a potent kinase inhibitor with specificity for the BRAF V600E mutation, for the treatment of metastatic melanoma. While this drug is otherwise well-tolerated, many patients develop cutaneous toxicities. This report demonstrates multiple cutaneous toxicities in a patient while undergoing treatment with vemurafenib.